Posted by Michael Wonder on 26 Mar 2021
FDA authorises marketing of device to improve gait in multiple sclerosis patients
26 March 2021 - Today, the U.S. FDA authorised marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis.
The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older.
The device, called Portable Neuromodulation Stimulator, is a neuromuscular tongue stimulator that consists of a non-implantable apparatus to generate electrical pulses for stimulation of the trigeminal and facial nerves via the tongue to provide treatment of motor deficits.
